Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Löwenberg B.
Döhner H, et al. Among authors: larson ra.
Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409.
Blood. 2024.
PMID: 39133932